Abstract:
The present invention relates to an improved process for the preparation of Cefozopran of formula (I), as well as pharmaceutical composition of Cefozopran.(Formula 1) (I) Said process comprises the steps of a) addition of sodium chloride and sodium carbonate to a solution of Cefozopran and b) washing said solution using (a) water immiscible organic solvent(s).
Abstract:
The present invention relates to an improved process for the preparation of Cefozopran of formula (I), its hydrochloride, its hydrate and its solvate. The present invention more particularly provides a process for preparing Cefozopran hydrochloride IPA solvate, novel crystalline forms of Cefozopran hydrochloride or its hydrate and an improved process for the preparation of pharmaceutical composition of Cefozopran.
Abstract:
The present invention is to relate an improved process using anisole as solvent for the preparation of compound of formula (I) and its pharmaceutically acceptable salts thereof. wherein R represents-NR 1 R 2 , or formula (II), a group n = 1,2,3,4 and 5, where R 1 and R2 may be same or different and independently represents hydrogen, or C 1-6 alkyl;
Abstract translation:本发明涉及使用苯甲醚作为制备式(I)化合物及其药学上可接受的盐的溶剂的改进方法。 其中R表示-NR 1 R 2 R 2或式(II),n = 1,2,3,4和5组,其中R 1, / SUB和R 2可以相同或不同,并且独立地表示氢或C 1-6烷基;
Abstract:
The present invention relates to the process for the preparation of monobactam antibiotic of formula (I). More particularly, the present invention relates to the preparation of Aztreonam of formula (I) from its precursor, tertiary butyl ester of Aztreonam of formula (II).
Abstract:
The present invention provides a novel process for preparing a 2b-heterocyclyl methyl penam derivatives of the formula (I): (I)where R1 represents hydrogen, carboxylic acid protecting group such as an ester or a pharmaceutically acceptable salt; R2 and R3 may be same or different and independently represent hydrogen, halogen, NH2, acylamino, phthalimido with a proviso that both R2 and R3 are not NH2, acylamino, phthalimido; Het represents a 5 or 6-membered NH containing heterocycle ring system containing one or more heteroatoms selected from O, S, or N, which comprises :(i) reacting a compound of formula (VII) where L represents a leaving group with a compound of formula (VIII) where Het is as defined earlier in the presence of a solvent and base at a temperature in the range of -10 to 110 °C to produce a compound of formula (IX); (ii) oxidizing the compound of formula (IX) using conventional oxidizing agents in the presence of water miscible solvent and an organic acid to produce a compound a formula (I) and if necessary; and (iii) de-esterifying the compound of formula (I) where R1 represents a carboxy protecting group to a compound of formula (I) where R1 represents hydrogen using metal catalyst, in the presence of a base and water immiscible solvent.
Abstract:
The present invention relates to an improved process for the preparation of the carbapenem antibiotic of formula (I) or its salts, hydrates and esters. The present invention further provides novel crystalline form of compound of general formula (III), wherein R 3 is p-nitrobenzyloxy carbonyl.
Abstract:
The present invention relates to a process for the production of cephalosporin antibiotic intermediate of formula (I). More particularly relates to the preparation of the compound of formula (I) using a solvent medium selected from the group consisting of decalin (decahydronapthalene), hexane, cyclohexene, tetralin, petroleum ether, wherein X represents HI, HCI, H2SO4 and the like. The compound of formula (I) is an important intermediate in the preparation of Cefepime.
Abstract translation:本发明涉及制备式(I)的头孢菌素抗生素中间体的方法。 更具体地涉及使用选自十氢萘(十氢萘),己烷,环己烯,四氢化萘,石油醚,其中X代表HI,HCl,H 2 SO 4等的溶剂介质制备式(I)化合物。 式(I)化合物是头孢吡肟制剂中的重要中间体。
Abstract:
The present invention relates to a new stereoselective method for the preparation of tris-O-substituted-(E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl) ethene of the formula (I) which is a key intermediate in the synthesis of trans-resveratrol (I-, R 1 =R 2 =R 3 =H). The invention also provides a method for the exclusive synthesis of trans-isomer of compounds of formula (I) without any contamination of cis-isomer.
Abstract:
The present invention relates to novel polymorphs of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of novel polymorphs of crystalline Ceftiofur sodium of formula (I).